Appeal finds NICE decision on £90k breast cancer drug 'unfair'

M134901 Breast cancer  CT scan SPL

The impact of the government’s drug pricing deal on patient access to new medicines has been thrown into confusion after a pharmaceutical company’s appeal against the decision to ban routine NHS funding of one of its drugs was upheld.

You need to be signed in to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of HSJ.co.uk and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Alternatively, click here to register for free to keep reading this article and to receive our daily news alerts

Sign into your account here